All In Biotech

Drug Trial Radar · NCT03278509

Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)

Randomized Evaluation of Decreased Usage of betablocCkErs After Myocardial Infarction in the SWEDEHEART Registry - A Registry-based, Randomized, Parallel, Open-label, Multicenter Trial (REDUCE-SWEDEHEART)

Last checked: Nov 19, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

5,000

Planned (sponsor's estimate)

Start

Sep 11, 2017

Primary completion

Nov 16, 2023

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Karolinska InstitutetAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Uppsala University; The Swedish Research Council
First posted
Sep 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long-term beta-blocker therapy has not been investigated in contemporary randomized clinical trials in patients with myocardial infarction and normal heart function. The aim of this study is to determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic ejection fraction reduces the composite of death of any cause or new myocardial infarction..

Conditions

  • Acute Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction
  • ST Elevation Myocardial Infarction

Interventions

  • Metoprolol SuccinateDrug

    Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).

  • BisoprololDrug

    Please see the section above.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the composite of death of any cause or MITime frame: through study completion, an average of 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Danderyd Hospital, Cardiac Intensive Care

    Danderyd, Stockholm County, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.